UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the US.
Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.
Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).
Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.
WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash.
Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Pfizer has announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Massachusetts.
Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.